1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

Recruiting now · Not applicable

Conditions studied: Scarring Alopecia, Androgenetic Alopecia

In brief

Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.

Key facts

Study ID

NCT05460611

Run by

Montefiore Medical Center

People needed

10

Starts

2023-12-07

Expected to finish

2028-07-01

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss
• Subject must voluntarily sign and date an IRB approved informed consent form
• Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months
• Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months
• Able to read, understand and voluntarily provide written informed consent
• Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regimen during the study
• Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements
• Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period

You may not qualify if…

• Subject does not have the capacity to consent to the study
• Subject has other types of alopecia of the scalp like alopecia areata
• History of intralesional steroid injections to the scalp in the last 12 months
• Pregnant women
• Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject
• Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months
• Allergy or history of prior reaction to lidocaine
• History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months
• History or current use of the following prescription medications:
• i. Immunosuppressive medications/biologics, 6 months prior to and during the study ii. Accutane or other systemic retinoids within the past twelve months
• Smoking or vaping in the past 12 months
• History of uncontrolled hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders
• History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism

Where it is running

• Montefiore Einstein Advanced Care — Elmsford, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.